Biosimilar Reimbursement Under The Sequester: The Lower The Price, The Bigger The Spread
This article was originally published in RPM Report
Novartis has become the first company to announce a biosimilar application in the US, and will likely become the first company to test the Medicare reimbursement formula for the new product class. The 2% sequester cut in Medicare may actually make that formula more attractive for biosimilars than the original law. Here’s how.